Mitochondrial metabolism reprogramming-mediated cardiomyocyte senescence involved in arsenic stress-evoked heart

Yán Wāng1, Yapeng Han2, De-Xiang Xu2

  • 1Department of Toxicology, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu 210009, China.

PubMed

Insights

Environmental arsenic exposure harms heart cells by disrupting mitochondrial energy production, leading to aging and dysfunction. Nicotinamide mononucleotide (NMN) and Mito-TEMPO show promise in protecting against arsenic-induced cardiac damage.

Area of Science:

  • Environmental toxicology
  • Cardiovascular research
  • Mitochondrial biology

Background:

  • Chronic inorganic arsenic exposure is linked to cardiotoxicity.
  • Mechanisms underlying arsenic-induced heart damage are not fully understood.

Purpose of the Study:

  • Investigate how arsenite disrupts mitochondrial metabolism, specifically the tricarboxylic acid (TCA) cycle.
  • Determine the role of TCA cycle dysfunction in cardiomyocyte senescence and cardiac aging.
  • Explore potential therapeutic interventions for arsenic-induced cardiotoxicity.

Main Methods:

  • Proteomics and metabolomics analysis of arsenic-exposed cardiomyocytes.
  • In vivo studies involving chronic arsenite exposure in rodents.
  • In vitro experiments using human cardiomyocyte cell lines (AC16).
  • Assessment of senescence markers (CDKN1A, NPPB) and cardiac function.
  • Evaluation of therapeutic effects of nicotinamide mononucleotide (NMN) and Mito-TEMPO.

Main Results:

  • Arsenic exposure altered mitochondrial electron transport chain (ETC) proteins and impaired key TCA cycle enzymes.
  • In vivo and in vitro studies showed arsenic induced early cardiomyocyte senescence and cardiac aging.
  • Sub-cytotoxic arsenite doses impaired TCA cycle function before senescence and injury.
  • NMN and Mito-TEMPO treatments mitigated senescence, improved cardiac function, and restored TCA cycle activity.

Conclusions:

  • Mitochondrial metabolic reprogramming is central to arsenic-induced cardiomyocyte aging and dysfunction.
  • Targeting mitochondrial metabolism offers a potential strategy to mitigate arsenic cardiotoxicity.
  • NMN and Mito-TEMPO demonstrate therapeutic potential against arsenic-induced cardiac damage.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
15.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
55
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511